Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.
- Merck & Co Inc (NYSE:MRK) Q2 sales reached $11.4 billion, +22% Y/Y, missing the consensus of $11.5 billion. Excluding the foreign exchange impact, revenues were up 19%, reflecting ongoing recovery from the COVID-19 pandemic and underlying solid demand.
- Pharmaceutical sales increased 22% to $10 billion. Keytruda sales grew 23% to $4.2 billion, excluding forex impact sales were up 20%.
- Vaccine sales rebounded, and Gardasil/ Gardasil 9 sales were up 88% to $1.2 billion.
- Animal Health revenue expanded 34% to $1.5 billion.
- Adjusted EPS of $1.31 also came in below the analysts' estimate of $1.44.
- 2021 Guidance: Merck trims sales outlook to $46.4 billion - $47.4 billion (consensus $48.59 billion) versus earlier outlook of $51.8 billion - $53.8 billion (included Organon).
- It expects an adjusted EPS of $5.47 - $5.57 (consensus $6.15).
- Price Action: MRK shares are down 1.34% at $77.28 during the premarket session on the last check Thursday.
- Image by Arek Socha from Pixabay
Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!